Veniti’s 200-patient, 60-month Virtus trial, run under an investigational device exemption from the FDA, is a single-arm safety & efficacy study with a main safety endpoint of major adverse events within 30 days and an efficacy endpoint of primary patency rate, according to ClinicalTrials.gov. Final data collection is slated for May 2017.
“We are extremely pleased to be partnering with such a high quality industry leader to advance our core technology, the Vici venous stent,” president & CEO Jeff Elkins said in prepared remarks. “This financing will allow us to complete a number of critical milestones and support more physicians treating patients suffering from venous outflow obstruction around the world.”
Veniti, which won CE Mark approval in the European Union in November 2013 for the Vici stent, raised a $13.5 million Series A round in March 2011. A Series B round in July 2013 pulled in another $11 million, according to the company’s website, followed by a $17 million Series C in March 2015.